APA (7th ed.) Citation

SE, A., RD, H., C, P., HG, K., GM, H., KB, L., . . . A, T. (2016). Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The Lancet. Oncology, 17(12), 1697. https://doi.org/10.1016/S1470-2045(16)30531-9

Chicago Style (17th ed.) Citation

SE, Al-Batran, et al. "Histopathological Regression After Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin Versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine in Patients with Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results from the Phase 2 Part of a Multicentre, Open-label, Randomised Phase 2/3 Trial." The Lancet. Oncology 17, no. 12 (2016): 1697. https://doi.org/10.1016/S1470-2045(16)30531-9.

MLA (9th ed.) Citation

SE, Al-Batran, et al. "Histopathological Regression After Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin Versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine in Patients with Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results from the Phase 2 Part of a Multicentre, Open-label, Randomised Phase 2/3 Trial." The Lancet. Oncology, vol. 17, no. 12, 2016, p. 1697, https://doi.org/10.1016/S1470-2045(16)30531-9.